- Home
- MGLD vs ELTX Comparison
MGLD vs ELTX Comparison
Compare MGLD & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGLD | ELTX |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 209.9M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MGLD | ELTX |
|---|---|---|
| Price | $1.22 | $10.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 19.2K | ★ 139.0K |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,876,734.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $4.60 |
| 52 Week High | $1.38 | $14.93 |
Technical Indicators
Market Signals| Indicator | MGLD | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 48.63 |
| Support Level | $0.86 | $9.84 |
| Resistance Level | $1.37 | $11.12 |
| Average True Range (ATR) | 0.08 | 1.00 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 60.00 | 15.82 |
Price Performance
Historical ComparisonAbout MGLD The Marygold Companies Inc.
The Marygold Companies Inc is an international holding company focused on acquiring and growing profitable businesses. Its main segments include U.S. Fund Management through USCF Investments, Food Products via Gourmet Foods and Printstock Products in New Zealand, Beauty Products under the Original Sprout brand, and formerly Security Systems through Brigadier, sold in 2025. The majority of revenue comes from fund management. The company operates in the USA, New Zealand, the United Kingdom, and Canada, with the majority of revenue generated from the USA. Its business approach focuses on strengthening financial services, expanding fintech, and managing a diverse portfolio for growth.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.